Robert W. Mcnutt | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Robert W. Mcnutt is active.

Explore More

Publication

Featured researches published by Robert W. Mcnutt.

Bioorganic & Medicinal Chemistry Letters | 2000

The discovery of potent cRaf1 kinase inhibitors.

Karen Lackey; Michael Cory; Ronda Davis; Stephen V. Frye; Philip A. Harris; Robert Neil Hunter; David K. Jung; O.Bradley McDonald; Robert W. Mcnutt; Michael Robert Peel; Randy D. Rutkowske; James M. Veal; Edgar R. Wood

A series of benzylidene-1H-indol-2-one (oxindole) derivatives was synthesized and evaluated as cRaf-1 kinase inhibitors. The key features of the molecules were the donor/acceptor motif common to kinase inhibitors and a critical acidic phenol flanked by two substitutions. Diverse 5-position substitutions provided compounds with low nanomolar kinase enzyme inhibition and inhibited the intracellular MAPK pathway.

Bioorganic & Medicinal Chemistry Letters | 1995

AN EFFICIENT SYNTHESIS OF THE BENZHYDRYLPIPERAZINE DELTA OPIOID AGONIST (+)-BW373U86

Michael J. Bishop; Robert W. Mcnutt

A diastereoselective version of Katritzkys method for tertiary amine formation provides an efficient route to the highly selective, non-peptidal, delta opioid agonist (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl]-N,N-diethylbenzamide [(+)-BW373U86], 1.

Archive | 1998

Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases

Scott Howard Dickerson; Philip A. Harris; Robert Neil Hunter; David K. Jung; Karen Lackey; Robert W. Mcnutt; Michael Robert Peel; James M. Veal

Archive | 2000

3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors

Karen Elizabeth Lackey; Robert W. Mcnutt

Journal of Pharmacology and Experimental Therapeutics | 1997

Antagonistic Modulation Between the Delta Opioid Agonist BW373U86 and the Mu Opioid Agonist Fentanyl in Mice

Scott J. O'Neill; Collins Ma; Hugh O. Pettit; Robert W. Mcnutt; Kwen-Jen Chang

Journal of Pharmacology and Experimental Therapeutics | 2003

DPI-3290 [(+)-3-((α-R)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A Mixed Opioid Agonist with Potent Antinociceptive Activity

Peter J. Gengo; Hugh O. Pettit; Scott J. O'Neill; Ke Wei; Robert W. Mcnutt; Michael J. Bishop; Kwen-Jen Chang

Archive | 1997

Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds

Kwen-Jen Chang; Robert W. Mcnutt; Hugh O. Pettit; Michael J. Bishop

Journal of Pharmacology and Experimental Therapeutics | 2003

DPI-3290 [(+)-3-((α-R)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. II. A Mixed Opioid Agonist with Potent Antinociceptive Activity and Limited Effects on Respiratory Function

Peter J. Gengo; Hugh O. Pettit; Scott J. O'Neill; Ying Fu Su; Robert W. Mcnutt; Kwen-Jen Chang

Journal of Medicinal Chemistry | 2003

3-(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-alkyl-N-arylbenzamides: potent, non-peptidic agonists of both the micro and delta opioid receptors.

Michael J. Bishop; Dulce Maria Garrido; G. Evan Boswell; Mark A. Collins; Philip A. Harris; Robert W. Mcnutt; Scott J. O'Neill; Ke Wei; Kwen-Jen Chang

Archive | 2001